On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Glaxosmithkline (Finland)

InstitutionResearch output, impact & collaborations

Glaxosmithkline (Finland) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Glaxosmithkline (Finland)?

ScholarIQrecord summary

Glaxosmithkline (Finland) is a research organisation in Espoo, FI. OpenAlex records 312 works and 12,778 citations for it. 146 researchers list it as their most recent affiliation.

How many works does Glaxosmithkline (Finland) have?

ScholarIQindexed works

Glaxosmithkline (Finland) has 312 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Glaxosmithkline (Finland) →

How many citations does Glaxosmithkline (Finland) have?

ScholarIQcitation count

Glaxosmithkline (Finland) has 12,778 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Glaxosmithkline (Finland) →

How many researchers are at Glaxosmithkline (Finland)?

ScholarIQresearcher count

Glaxosmithkline (Finland) has 146 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Glaxosmithkline (Finland)?

ScholarIQavg h-index

Glaxosmithkline (Finland) has an average h-index of 46 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Glaxosmithkline (Finland)?

ScholarIQror

The ROR for Glaxosmithkline (Finland) is on the source record.

Open the ROR →

What is the OpenAlex record for Glaxosmithkline (Finland)?

ScholarIQopenalex

The OpenAlex for Glaxosmithkline (Finland) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Glaxosmithkline (Finland)?

ScholarIQtop researchers by citations

Roger A. Levy · Systemic Lupus Erythematosus Research

280 works11,798 citations

What are the most-cited papers on Glaxosmithkline (Finland)?

ScholarIQmost cited works

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher, Stephen Hall, Roger A. Levy, Renato Jimenez, Edmund KM Li, Mathew Thomas, Ho‐Youn Kim, Manuel Gustavo Leon, C Tănăsescu, Е. Л. Насонов, Joung-Liang Lan, Lilia Pineda, Z. John Zhong, William W. Freimuth, Michelle Petri

The Lancet. 20112,071 Citations

Catastrophic Antiphospholipid Syndrome: Clinical and Laboratory Features of 50 Patients

Ronald A. Asherson, Ricard Cervera, Jean‐Charles Piette, Josep Font, J. T. Lie, Arsinur Burcoglu, Ken Lim, Francisco J. Muñoz, Roger A. Levy, François Boué, Jérôme Rossert, M Ingelmo

Medicine. 1998547 Citations

Anti-inflammatory and immunosuppressive drugs and reproduction.

Monika Østensen, Munther A. Khamashta, Michael D. Lockshin, Ann L. Parke, Antonio Brucato, Howard Carp, Andrea Doria, Raj Rai, Pier Luigi Meroni, Irene Cetin, Ronald H. W. M. Derksen, Ware Branch, Mario Motta, Caroline Gordon, Guillermo Ruiz‐Irastorza, Arsenio Spinillo, Deborah Friedman, Rolando Cimaz, Andrew E. Czeizel, Jean Charles Piette, Ricard Cervera, Roger A. Levy, Maurizio Clementi, Sara De Carolis, Michelle Petri, Yehuda Shoenfeld, David Faden, Guido Valesini, Anǵela Tincani

Arthritis Research & Therapy. 2006535 CitationsOPEN ACCESS

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double‐blind, placebo‐controlled trial in asymptomatic antiphospholipid antibody–positive individuals

Doruk Erkan, Melanie J. Harrison, Roger A. Levy, Margaret G. E. Peterson, Michelle Petri, Lisa R. Sammaritano, Aynur Ünalp–Arida, Verônica Silva Vilela, Yusuf Yazıcı, Michael D. Lockshin

Arthritis & Rheumatism. 2007401 Citations

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

Roger A. Levy, V.S. Vilela, M J Cataldo, Raquel Conceição de Almeida Ramos, J LMB Duarte, Bernardo Rangel Tura, Elise M. Albuquerque, Nilson Ramires de Jesús

Lupus. 2001398 Citations

How much of the research on Glaxosmithkline (Finland) is open access?

ScholarIQopen access share

38%OPEN ACCESS

Gold

25%

Green

Hybrid

13%

Bronze

Closed

63%